24/7 Market News Snapshot 23 September, 2025 – Soligenix, Inc. Common Stock (NASDAQ:SNGX)

September 23, 2025

DENVER, Colo., 23 September, 2025 (www.247marketnews.com) – (NASDAQ:SNGX) are discussed in this article.
Soligenix, Inc. (SNGX) has experienced a notable downturn in its stock price, currently trading at $2.285, reflecting a decline of approximately 1.93% from the previous close of $2.330. The company has observed heightened trading activity, with a volume of 2.70 million shares exchanged, indicating increased investor engagement that often accompanies volatility. This bearish trend has prompted traders to adopt a cautious approach, particularly as they monitor critical support levels; a breach below $2.25 could signal further declines, while resistance at $2.35 may present an opportunity for a market rebound.

In a significant strategic development, Soligenix has appointed Dr. Tomas J. Philipson as a Strategic Advisor to bolster its leadership team. Dr. Philipson brings extensive experience in economic and healthcare policy, having held pivotal roles including vice chairman of the White House Council of Economic Advisers and advisor positions at the FDA and CMS. His background in diverse healthcare initiatives, including being a managing partner at MEDA Ventures, positions him uniquely to contribute to Soligenix’s growth trajectory.

“The addition of Dr. Philipson is an exciting development for Soligenix,” stated Christopher J. Schaber, PhD, President and CEO. He highlighted how Dr. Philipson’s expertise will be instrumental as the company advances HyBryte™, its leading candidate for treating cutaneous T-cell lymphoma, currently in a confirmatory Phase 3 clinical trial. With positive clinical outcomes and designations as an orphan drug and fast track therapy, HyBryte™ aims to address significant unmet medical needs.

Dr. Philipson expressed his eagerness to support Soligenix’s mission, emphasizing the importance of healthcare innovation and patient access. His appointment is seen as a crucial step forward for Soligenix as it navigates the complexities of drug development and regulatory approval processes.

Related news for (SNGX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.